{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:51:19Z","timestamp":1792007479369,"version":"4.4.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>The management of patients with complex comorbidity involving several organ systems can use an approach focused on each organ system independently or can use an approach trying to integrate various injuries and dysfunction into a single syndrome. Cardiorenal syndromes can develop with an initial injury to either the heart or kidney and then sequential involvement of the second organ. This can occur acutely or chronically. Cardiorenal syndrome type 3 is defined by acute renal injury with subsequent cardiac injury and\/or dysfunction. Studies on these patients must use strict inclusion criteria. Pavan reported information on 100 patients with acute kidney injury in India to determine the frequency of cardiorenal syndrome type 3. He excluded patients with significant prior comorbidity. The most frequent causes of acute kidney injury in these patients were drug toxicity, gastroenteritis with volume contraction, and obstetrical complications. This study included 100 patients with acute kidney injury, and 29 developed cardiorenal syndrome type 3. Important outcomes included frequent mortality and chronic renal failure. Other studies have reported that cardiorenal syndrome type 3 occurs relatively infrequently. The analysis of large data bases has demonstrated that the development of acute kidney injury in hospitalized patients has important consequences, including the development of heart failure and increased mortality, but the complexity of these cohorts makes it difficult to determine the time course for the development of multisystem disorders. The pathogenesis of cardiorenal syndrome type 3 involves mitochondrial dysfunction, immune dysregulation, and ischemia-reperfusion. Cardiac events occur secondary to fluid overload, electrolyte disorders, and uremic toxins. These patients need increased attention during hospitalization and outpatient management in an effort to slow the progression of the primary disorder and treat complications.<\/jats:p>","DOI":"10.1097\/crd.0000000000000491","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T12:07:03Z","timestamp":1665403623000},"page":"140-145","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Cardiorenal Syndrome Type 3 Review"],"prefix":"10.1097","volume":"32","author":[{"given":"Robin","family":"Okpara","sequence":"first","affiliation":[{"name":"From the Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo","family":"Pena","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Nugent","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association.","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"R2-20250619","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000313745","article-title":"Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI).","volume":"165","author":"Ronco","year":"2010","journal-title":"Contrib Nephrol"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2215\/CJN.10981016","article-title":"The diagnosis-wide landscape of hospital-acquired AKI.","volume":"12","author":"Jannot","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"R4-20250619","doi-asserted-by":"crossref","first-page":"148082","DOI":"10.1155\/2015\/148082","article-title":"Advances in the pathogenesis of cardiorenal syndrome type 3.","volume":"2015","author":"Clementi","year":"2015","journal-title":"Oxid Med Cell Longev"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.semnephrol.2011.11.005","article-title":"Cardio-renal syndrome type 3: epidemiology, pathophysiology, and treatment.","volume":"32","author":"Chuasuwan","year":"2012","journal-title":"Semin Nephrol"},{"key":"R6-20250619","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1053\/j.ajkd.2018.03.028","article-title":"Distant organ dysfunction in acute kidney injury: a review.","volume":"72","author":"Lee","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"R7-20250619","first-page":"42","article-title":"Incidence of acute cardiorenal syndrome type 3 in India.","volume":"8","author":"Pavan","year":"2014","journal-title":"Iran J Kidney Dis"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.4103\/jfmpc.jfmpc_533_20","article-title":"Prevalence, types, risk factors, and outcomes of cardiorenal syndrome in a rural population of central India: a cross-sectional study.","volume":"9","author":"Prothasis","year":"2020","journal-title":"J Family Med Prim Care"},{"key":"R9-20250619","first-page":"41","article-title":"Cardiorenal syndrome: clinical outcome study.","volume":"64","author":"Shah","year":"2016","journal-title":"J Assoc Physicians India"},{"key":"R10-20250619","doi-asserted-by":"crossref","first-page":"4895434","DOI":"10.1155\/2022\/4895434","article-title":"Kidney-related outcome in cardiorenal syndrome type 3.","volume":"2022","author":"Drubel","year":"2022","journal-title":"Int J Nephrol"},{"key":"R11-20250619","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfac153","article-title":"Long-term impact of cardiorenal syndromes on major outcomes based on their chronology: a comprehensive French nationwide cohort study.","author":"Halimi","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2215\/CJN.12591117","article-title":"Acute kidney injury and risk of heart failure and atherosclerotic events.","volume":"13","author":"Go","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"R13-20250619","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1053\/j.ajkd.2017.08.027","article-title":"Acute kidney injury and risk of incident heart failure among US veterans.","volume":"71","author":"Bansal","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrneph.2013.250","article-title":"Cardiorenal syndrome--current understanding and future perspectives.","volume":"10","author":"Braam","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/eurheartj\/ehi020","article-title":"The severe cardiorenal syndrome: \u201cGuyton revisited\u201d.","volume":"26","author":"Bongartz","year":"2005","journal-title":"Eur Heart J"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1056\/NEJMra1916393","article-title":"Cardiovascular consequences of acute kidney injury.","volume":"382","author":"Legrand","year":"2020","journal-title":"N Engl J Med"},{"key":"R17-20250619","doi-asserted-by":"crossref","first-page":"22","DOI":"10.14740\/jocmr4639","article-title":"Experimental cardiorenal syndrome type 3: what is known so far?","volume":"14","author":"Patschan","year":"2022","journal-title":"J Clin Med Res"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"e13357","DOI":"10.1111\/apha.13357","article-title":"Distant organ dysfunction in acute kidney injury.","volume":"228","author":"Husain-Syed","year":"2020","journal-title":"Acta Physiol (Oxf)"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"F589","DOI":"10.1152\/ajprenal.00372.2021","article-title":"Mitochondria as mediators of systemic inflammation and organ cross talk in acute kidney injury.","volume":"322","author":"Hepokoski","year":"2022","journal-title":"Am J Physiol Renal Physiol"},{"key":"R20-20250619","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10173991","article-title":"Targeting mitochondria and metabolism in acute kidney injury.","volume":"10","author":"Li","year":"2021","journal-title":"J Clin Med"},{"key":"R21-20250619","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1681\/ASN.2014080750","article-title":"Regulation of mitochondrial dynamics by dynamin-related protein-1 in acute cardiorenal syndrome.","volume":"26","author":"Sumida","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R22-20250619","doi-asserted-by":"crossref","first-page":"630412","DOI":"10.3389\/fcell.2021.630412","article-title":"Grb2 Induces cardiorenal syndrome type 3: roles of IL-6, cardiomyocyte bioenergetics, and Akt\/mTOR pathway.","volume":"9","author":"Wang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"R23-20250619","doi-asserted-by":"crossref","first-page":"1605358","DOI":"10.1155\/2020\/1605358","article-title":"Characterization of the oxidative stress in renal ischemia\/reperfusion-induced cardiorenal syndrome type 3.","volume":"2020","author":"Caio-Silva","year":"2020","journal-title":"Biomed Res Int"},{"key":"R24-20250619","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.3390\/cells10113029","article-title":"Mitochondrial dysfunction in cardiorenal syndrome 3: renocardiac effect of Vitamin C.","volume":"10","author":"Neres-Santos","year":"2021","journal-title":"Cells"},{"key":"R25-20250619","doi-asserted-by":"crossref","first-page":"11779322211027396","DOI":"10.1177\/11779322211027396","article-title":"In silico integrative approach revealed key MicroRNAs and associated target genes in cardiorenal syndrome.","volume":"15","author":"Ishrat","year":"2021","journal-title":"Bioinform Biol Insights"},{"key":"R26-20250619","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11255-021-02904-9","article-title":"Monocyte to HDL ratio: a novel marker of resistant hypertension in CKD patients.","volume":"54","author":"Gembillo","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"R27-20250619","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000444502","article-title":"Molecular and genetic mechanisms involved in the pathogenesis of cardiorenal cross talk.","volume":"83","author":"Virz\u00ec","year":"2016","journal-title":"Pathobiology"},{"key":"R28-20250619","doi-asserted-by":"crossref","first-page":"e12371","DOI":"10.14814\/phy2.12371","article-title":"Contribution of microRNA to pathological fibrosis in cardio-renal syndrome: impact of uremic toxins.","volume":"3","author":"Rana","year":"2015","journal-title":"Physiol Rep"},{"key":"R29-20250619","doi-asserted-by":"crossref","DOI":"10.3390\/biom11111581","article-title":"Cardiorenal syndrome: new pathways and novel biomarkers.","volume":"11","author":"Gembillo","year":"2021","journal-title":"Biomolecules"},{"key":"R30-20250619","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1038\/s41598-020-61836-z","article-title":"Circulating miRNA-21 as a diagnostic biomarker in elderly patients with type 2 cardiorenal syndrome.","volume":"10","author":"Wang","year":"2020","journal-title":"Sci Rep"},{"key":"R31-20250619","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/0886022X.2021.1891098","article-title":"MicroRNA-21-containing microvesicles from tubular epithelial cells promote cardiomyocyte hypertrophy.","volume":"43","author":"Di","year":"2021","journal-title":"Ren Fail"},{"key":"R32-20250619","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3389\/fphar.2020.00726","article-title":"miR-21, mediator, and potential therapeutic target in the cardiorenal syndrome.","volume":"11","author":"Huang","year":"2020","journal-title":"Front Pharmacol"},{"key":"R33-20250619","first-page":"194910","article-title":"Therapeutic options for the management of the cardiorenal syndrome.","volume":"2011","author":"Koniari","year":"2010","journal-title":"Int J Nephrol"},{"key":"R34-20250619","doi-asserted-by":"crossref","first-page":"j791","DOI":"10.1136\/bmj.j791","article-title":"Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study.","volume":"356","author":"Schmidt","year":"2017","journal-title":"BMJ"},{"key":"R35-20250619","first-page":"72","article-title":"New biomarkers of acute kidney injury and the cardio-renal syndrome.","volume":"31","author":"Hawkins","year":"2011","journal-title":"Korean J Lab Med"},{"key":"R36-20250619","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1523-1755.2004.00861.x","article-title":"Early detection of acute renal failure by serum cystatin C.","volume":"66","author":"Herget-Rosenthal","year":"2004","journal-title":"Kidney Int"},{"key":"R37-20250619","doi-asserted-by":"crossref","first-page":"9617363","DOI":"10.1155\/2018\/9617363","article-title":"Biomarkers in cardiorenal syndromes.","volume":"2018","author":"Fu","year":"2018","journal-title":"Biomed Res Int"},{"key":"R38-20250619","doi-asserted-by":"crossref","first-page":"868658","DOI":"10.3389\/fcvm.2022.868658","article-title":"Biomarkers in cardiorenal syndrome and potential insights into novel therapeutics.","volume":"9","author":"Chung","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R39-20250619","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1067\/mhj.2002.123144","article-title":"Diuretic resistance predicts mortality in patients with advanced heart failure.","volume":"144","author":"Neuberg","year":"2002","journal-title":"Am Heart J"},{"key":"R40-20250619","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure.","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"key":"R41-20250619","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccc.2015.06.006","article-title":"A Clinical approach to the acute cardiorenal syndrome.","volume":"31","author":"Jentzer","year":"2015","journal-title":"Crit Care Clin"},{"key":"R42-20250619","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cardfail.2014.03.006","article-title":"Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure.","volume":"20","author":"Singh","year":"2014","journal-title":"J Card Fail"},{"key":"R43-20250619","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1161\/CIRCULATIONAHA.117.030112","article-title":"Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury.","volume":"137","author":"Ahmad","year":"2018","journal-title":"Circulation"},{"key":"R44-20250619","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.cardfail.2004.06.018","article-title":"Randomized controlled trial of ultrafiltration versus usual care for hospitalized patients with heart failure: preliminary report of the rapid trial.","volume":"10","author":"Bart","year":"2004","journal-title":"J Card Fail"},{"key":"R45-20250619","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00134-018-5064-5","article-title":"Position paper for the organization of ECMO programs for cardiac failure in adults.","volume":"44","author":"Abrams","year":"2018","journal-title":"Intensive Care Med"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T12:03:31Z","timestamp":1750334611000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000491","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,10]]}}}